Apolipoprotein B Gene Polymorphisms and Dyslipidemia in HIV Infected Adult Zimbabweans



Vitaris Kodogo1, Danai Tavonga Zhou1, 2, *, Olav Oektedalen3, Kerina Duri4, Babill Stray-Pedersen5, Exnevia Gomo1
1 Department of Medical Laboratory Sciences, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe
2 Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway
3 Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway
4 Department of Immunology, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe
5 Institute of Clinical Medicine, University in Oslo, and Womens Clinic, Oslo University Hospital, Oslo, Norway


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 407
Abstract HTML Views: 416
PDF Downloads: 87
ePub Downloads: 59
Total Views/Downloads: 969
Unique Statistics:

Full-Text HTML Views: 257
Abstract HTML Views: 192
PDF Downloads: 69
ePub Downloads: 50
Total Views/Downloads: 568



© Kodogo et al.; Licensee Bentham Open

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Department of Medical Laboratory Sciences, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe; Tel: +263 4 791630-9; Mobile: +263 772 566 214; E-mail: d.t.zhou@medisin.uio.no


Abstract

Background:

Dyslipidemia does not occur in all HIV-infected or antiretroviral therapy-experienced patients suggesting role of host genetic factors but there is paucity of data on association between dyslipidemia and gene polymorphisms in Zimbabwe.

Objective:

To determine association of lipoprotein levels and apolipoprotein B polymorphisms in HIV-infected adults.

Method:

Demographic data were collected from 103 consenting patients; lipoprotein levels were determined and blood samples were successfully genotyped for both apolipoprotein B 2488C>T Xba1 and apolipoprotein B 4154G>A p.Gln4154Lys EcoR1 polymorphisms by real time polymerase chain reaction.

Results:

Mean age of genotyped patients was 40.3 ± 10.1 years, 68% were female; prevalence of dyslipidemia was 67.4%. Of 103 samples genotyped for apolipoprotein B Xba1 polymorphism, 76 (74%) were homozygous C/C, 24 (23%) were heterozygous C/T and only three (3%) were homozygous T/T. Apolipoprotein B EcoR1 polymorphism showed little variability, one participant had rare genotype A/A, 68.3% had wild type genotype G/G.

Conclusion:

Observed frequencies of apolipoprotein B XbaI and EcoRI polymorphisms matched other African studies. In spite of low numbers of rare variants, there was positive association between both total cholestrol and high density lipoprotein with ECoR1 wild type G/G genotype, suggesting that ECoRI 4154 G allele could be more protective against coronary heart disease than EcoR1 4154 A allele. There is need for further research at population level to confirm whether apolipoprotein B ECoR1 genotyping is useful for predicting risk of dyslipidemia in HIV patients in our setting.

Keywords: APOB, ART, CHD, Dyslipidemia, EcoR1, HIV, Lipoproteins, Xba1.